Annals of Surgical Oncology

, Volume 21, Issue 2, pp 401–407 | Cite as

Bone Marrow Micrometastases Do Not Impact Disease-Free and Overall Survival in Early Stage Sentinel Lymph Node–Negative Breast Cancer Patients

  • Igor Langer
  • Ulrich Guller
  • Mathias Worni
  • Gilles Berclaz
  • Gad Singer
  • Gabriel Schaer
  • Mathias K. Fehr
  • Thomas Hess
  • Carsten Viehl
  • Lucio Bronz
  • Beate Schnarwyler
  • Edward Wight
  • Eduard Infanger
  • Daniel Burger
  • Ossi R. Koechli
  • Markus Zuber
  • for the Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer
Breast Oncology

Abstract

Background

The presence of lymph node metastases is the most important prognostic factor in early stage breast cancer. Whether bone marrow micrometastases (BMM) impact the prognosis in sentinel lymph node (SLN)–negative breast cancer patients remains a matter of debate. Therefore, the objective of this study was to assess the impact of BMM on 5-year disease-free and overall survival among those patients.

Methods

We analyzed 410 patients with early stage breast cancer (pT1 and pT2 ≤ 3 cm, cN0) who were prospectively enrolled into the Swiss Multicenter Sentinel Lymph Node Study in Breast Cancer between January 2000 and December 2003. All patients underwent bone marrow aspiration followed by SLN biopsy. All SLN were stained with hematoxylin and eosin and immunohistochemistry (Lu-5, CK-22). Cancer cells in the bone marrow were identified after staining with monoclonal antibodies A45-B/B3 against CK-8, -18, and -19.

Results

Negative SLN were found in 67.6 % (277 of 410) of the enrolled patients. Of those, BMM status was negative in 75.8 % (210 of 277) and positive in 24.2 % (67 of 277) patients. Median follow-up was 61 (range 11–96) months. Five-year disease-free survival was 93.6 % (95 % confidence interval [CI] 89.1–96.0) in BMM-negative and 92.2 % (95 % CI 82.5–96.2) in BMM-positive patients (p = 0.50). Five-year overall survival was 92.7 % (95 % CI 87.9–95.8) for the BMM-negative and 92.5 % (95 % CI 83.4–96.2) for the BMM-positive group (p = 0.85).

Conclusions

This is one of the first prospective studies to examine 5-year disease-free and overall survivals in SLN-negative patients in correlation to their BMM status. Although BMM are identified in one of four SLN-negative patients, they do not impact disease-free and overall survival.

References

  1. 1.
    Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245:452–61.PubMedCrossRefGoogle Scholar
  2. 2.
    de Boer M, van Dijck JA, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410–25.PubMedCrossRefGoogle Scholar
  3. 3.
    Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001;19:1468–75.PubMedGoogle Scholar
  4. 4.
    Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Dearnaley DP, Sloane JP, Ormerod MG, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer. 1981;44:85–90.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev. 2000;26:53–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Mansi JL, Gogas H, Bliss JM, et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999;354:197–202.PubMedCrossRefGoogle Scholar
  9. 9.
    Wiedswang G, Borgen E, Schirmer C, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2006;118:2013–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802.PubMedCrossRefGoogle Scholar
  11. 11.
    Langer I, Guller U, Koechli OR, et al. Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study. Ann Surg Oncol. 2007;14:1896–903.PubMedCrossRefGoogle Scholar
  12. 12.
    Saha S, Ali S, Ghanem M, et al. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer. Ann Surg Oncol. 2009;16:276–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Trocciola SM, Hoda S, Osborne MP, et al. Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients? J Am Coll Surg. 2005;200:720–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Sola M, Margeli M, Castella E, et al. Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study. BMC Cancer. 2011;11:252.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Molino A, Colombatti M, Bonetti F, et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer. 1991;67:1033–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Osborne MP, Wong GY, Asina S, et al. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res. 1991;51:2706–9.PubMedGoogle Scholar
  18. 18.
    Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Fortunato L, Mascaro A, Baldi A, et al. Positive bone marrow biopsy is associated with a decreased disease-free survival in patients with operable breast cancer. Ann Surg Oncol. 2009;16:3010–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Katz MH. Multivariable analysis: a practical guide for clinicians. 3rd ed. Cambridge: Cambridge University Press; 2011.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Igor Langer
    • 1
  • Ulrich Guller
    • 2
    • 3
  • Mathias Worni
    • 3
  • Gilles Berclaz
    • 4
  • Gad Singer
    • 5
  • Gabriel Schaer
    • 6
  • Mathias K. Fehr
    • 7
  • Thomas Hess
    • 8
  • Carsten Viehl
    • 9
  • Lucio Bronz
    • 10
  • Beate Schnarwyler
    • 11
  • Edward Wight
    • 12
  • Eduard Infanger
    • 13
  • Daniel Burger
    • 14
  • Ossi R. Koechli
    • 15
  • Markus Zuber
    • 16
  • for the Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer
  1. 1.Department of SurgeryLindenhof HospitalBerneSwitzerland
  2. 2.Division of Medical Oncology and HematologyKantonsspital St. GallenSt. GallenSwitzerland
  3. 3.Department of SurgeryUniversity Hospital BerneBerneSwitzerland
  4. 4.Division of GynecologyEngeriedspitalBerneSwitzerland
  5. 5.Institute of PathologyKantonsspital BadenBadenSwitzerland
  6. 6.Department of Obstetrics and GynecologyKantonsspital AarauAarauSwitzerland
  7. 7.Division of GynecologyKantonsspital FrauenfeldFrauenfeldSwitzerland
  8. 8.Division of GynecologyKantonsspital WinterthurWinterthurSwitzerland
  9. 9.Department of SurgeryUniversity Hospital BaselBaselSwitzerland
  10. 10.Department of Obstetrics and GynecologyOspedale San GiovanniBellinzonaSwitzerland
  11. 11.Private PracticeZurichSwitzerland
  12. 12.Division of GynecologyUniversity Hospital BaselBaselSwitzerland
  13. 13.Department of Obstetrics and GynecologyKantonales Spital Sursee-WolhusenSurseeSwitzerland
  14. 14.Department of Obstetrics and GynecologyHospital LachenLachenSwitzerland
  15. 15.Bethanien ClinicZurichSwitzerland
  16. 16.Department of SurgeryKantonsspital OltenOltenSwitzerland

Personalised recommendations